Evolent Health (NYSE:EVH) Stock Rating Upgraded by Wall Street Zen

Evolent Health (NYSE:EVH) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

EVH has been the subject of a number of other research reports. BTIG Research cut their price target on shares of Evolent Health from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday. Piper Sandler set a $6.00 target price on shares of Evolent Health in a research report on Tuesday, December 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evolent Health in a report on Monday, December 29th. Royal Bank Of Canada reduced their price target on shares of Evolent Health from $5.00 to $3.00 and set a “sector perform” rating for the company in a research report on Wednesday. Finally, Citizens Jmp decreased their price target on Evolent Health from $11.00 to $10.00 and set a “market outperform” rating on the stock in a research note on Tuesday, January 6th. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $6.50.

Evolent Health Stock Down 2.0%

EVH opened at $3.26 on Friday. The company has a debt-to-equity ratio of 1.25, a current ratio of 1.33 and a quick ratio of 1.33. The business has a 50 day simple moving average of $3.49 and a 200-day simple moving average of $5.80. The stock has a market capitalization of $363.26 million, a P/E ratio of -0.63 and a beta of 0.27. Evolent Health has a 12 month low of $2.50 and a 12 month high of $12.06.

Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Tuesday, February 24th. The technology company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The firm had revenue of $468.72 million for the quarter, compared to analyst estimates of $468.48 million. Evolent Health had a positive return on equity of 1.30% and a negative net margin of 28.49%.Evolent Health’s quarterly revenue was down 27.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.02) earnings per share. On average, equities analysts anticipate that Evolent Health will post 0.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC lifted its stake in shares of Evolent Health by 88.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company’s stock valued at $29,000 after buying an additional 1,194 shares during the period. CIBC Private Wealth Group LLC raised its holdings in Evolent Health by 4,000.0% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,100 shares of the technology company’s stock valued at $35,000 after acquiring an additional 4,000 shares during the last quarter. Strs Ohio purchased a new position in shares of Evolent Health during the 1st quarter worth $47,000. Vise Technologies Inc. purchased a new position in shares of Evolent Health during the 4th quarter worth $50,000. Finally, Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Evolent Health during the third quarter worth $51,000.

Evolent Health News Roundup

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: BTIG set a new $8.00 price target for EVH, signaling confidence that the stock has upside from current levels. Evolent Health (NYSE:EVH) Given New $8.00 Price Target at BTIG Research
• Positive Sentiment: UBS lowered its target to $5.00 but kept a “buy” rating, implying upside (reported as ~54% above the then-current price). UBS lowers price target to $5.00
• Positive Sentiment: Citigroup cut its target to $4.00 but maintained a “buy” rating, which suggests analysts still see recovery potential despite near-term weakness. Citigroup lowers price target to $4.00
• Positive Sentiment: Seeking Alpha published a bullish-themed piece arguing EVH is “cheap, levered, but ready to rebound,” which can attract value-oriented buyers. Evolent Health: Cheap, Levered, But Ready To Rebound
• Neutral Sentiment: Evolent announced executive participation in upcoming investor conferences with live webcasts — useful for transparency but unlikely to move the stock materially on its own. Evolent to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Yahoo Finance ran a roundup noting a sharp intraday move earlier; such coverage increases attention/volatility but doesn’t change fundamentals. Evolent Health (EVH) Shares Skyrocket, What You Need To Know
• Neutral Sentiment: Royal Bank of Canada set a $3.00 target — a lower valuation point that may anchor some expectations but was published alongside other divergent targets. Evolent Health (NYSE:EVH) Given New $3.00 Price Target at Royal Bank Of Canada
• Neutral Sentiment: Needham published a $4.00 price target; another mid-range projection adding to the wide spread of analyst views. Evolent Health (NYSE:EVH) Given New $4.00 Price Target at Needham & Company LLC
• Negative Sentiment: KeyCorp lowered EVH to “Sector Weight” (a downgrade), which is a clear negative signal and likely contributed to selling pressure. Evolent Health (NYSE:EVH) Rating Lowered to “Sector Weight” at KeyCorp

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.